Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03278964
Other study ID # 39748114.0.0000.0068
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 5, 2015
Est. completion date January 31, 2019

Study information

Verified date August 2019
Source University of Sao Paulo General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized prospective clinical trial, aiming to compare two techniques of orbital decompression. Patients with Graves orbitopathy in the inactive phase for at least 6 months will be divided in two groups; one group will be submitted to orbital decompression by antro-ethmoidal technique; the other group will be submitted to orbital decompression by lateral wall technique. Patients will be followed up for a period of 6 months after the surgery, and will be evaluated about the effect of orbital decompression on ocular motility, proptosis, ocular surface and quality of life.


Description:

Graves' orbitopathy is the most relevant non-thyroid manifestation of Graves' disease. Its clinical status varies from subclinical to severe deformities. Clinical features include palpebral retraction, exophthalmos, restrictive strabismus, chemosis, ocular surface lesions and optic neuropathy. There are two stages of the disease. There is an active phase in which the inflammatory process is present and the orbital changes evolve. The inactive phase comprises a stable clinical picture regarding the sequelae of the active phase. Orbital decompression surgery is the main treatment procedure for this inactive phase for functional and cosmetic rehabilitation purposes. In the last decades, great advances in the techniques and indication of this surgery have been observed. However, a consensus about the ideal technique does not yet exist. The most commonly used techniques are antro-ethmoidal decompression and lateral wall decompression alone or associated with other walls. The present study will be based on patients with Graves' orbitopathy diagnosis for at least 2 years and who are already in the inactive phase for at least 6 months. There are no prospective studies comparing the 2 main orbital decompression techniques through a detailed analysis of surgical outcomes from computed tomography images, digital photographic images and ocular motility examination. These informations will be collected in the preoperative and postoperative periods. The investigators will evaluate the decompressive potential of each technique calculated by the tomographic images. Participants will be followed up for a period of 6 months after the surgical procedure and the effect of decompression on ocular motility, ocular bulb positioning, ocular surface, vertical palpebral fissure, and the patient's quality of life will also be analyzed. The findings of this work will bring important contribution to the improvement of this surgical procedure of great relevance in the rehabilitation of patients with Graves' orbitopathy.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date January 31, 2019
Est. primary completion date January 31, 2019
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of Graves orbitopathy for at least 2 years

- Clinical Activity Score (CAS) < 4 for at least 6 months

- Agreement with the Informed Consent Form, which will be signed during the selection visit

- Ability to come to periodic evaluations for 6 months after the orbital decompression

- Absence of ocular abnormalities such as degenerative myopia, microphthalmia or anophthalmic cavity

- Absence of orbital abnormalities such as previous fractures or congenital defects

- Good collaboration for the exams

- Euthyroidism

- Exophthalmus = 20 mm in Hertel's exophthalmometry

- Preoperative clinical evaluation indicating absence of contraindications for a surgical procedure

Exclusion Criteria:

- Myasthenia gravis

- Pregnancy

- Previous orbital, strabismus or eyelid surgery

- Other abnormal eye conditions or symptoms that make it impossible to admit the patient to the study, according to the clinical judgment of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Orbital decompression


Locations

Country Name City State
Brazil University of Sao Paulo General Hospital São Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Ocular Motility status Measure by prism and cover, to assess strabismus in the nine positions of gaze Before orbital decompression and 1, 3 and 6 months after surgery
Primary Exophthalmos Exophthalmos will be measured by Hertel's exophthalmometer and orbital computerized tomography Before orbital decompression and 6 months after surgery
Secondary Diplopia Evaluation by Gorman's Diplopia Table Before orbital decompression and 1, 3 and 6 months after surgery
Secondary Digital photography evaluation Using digital photography, Photoshop and Image J, ductions and versions will be analyzed Before orbital decompression and 6 months after surgery
Secondary Volume of the extraocular muscles Measure by orbital computerized tomography images Before orbital decompression and 6 months after surgery
Secondary Ocular surface evaluation Assessed by Lysozyme Green, Break-up time, Schirmer I test Before orbital decompression and 6 months after surgery
Secondary Quality of life questionary Quality of life questionary GO-QoL form Before orbital decompression and 6 months after surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05532072 - Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy. Early Phase 1
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT05678374 - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Recruiting NCT03708627 - Bimatoprost as a Treatment for Graves' Orbitopathy Early Phase 1
Not yet recruiting NCT06413043 - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy N/A
Withdrawn NCT01379196 - Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy Phase 1/Phase 2
Recruiting NCT06275373 - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Recruiting NCT05126147 - Hydroxychloroquine in Mild Graves' Orbitopathy Phase 4
Recruiting NCT01999790 - Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy N/A
Recruiting NCT03066076 - Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Phase 3
Active, not recruiting NCT03122847 - Glucocorticoids and Bone in Graves' Ophthalmopathy
Terminated NCT01893450 - Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment N/A
Completed NCT00348413 - Thyroid Treatment Trial N/A
Completed NCT03498417 - Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
Not yet recruiting NCT04598815 - Sirolimus for Graves' Orbitopathy (GO) Phase 2
Terminated NCT01114503 - A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Phase 2
Completed NCT05775185 - Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
Completed NCT05793359 - Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy